Your privacy is very important to us.When you visit our website,please agree to the use of all cookies.For more information about personal data processing,please go t0 《Privacy Policy Statement》

a1_icon1.svg
Sufficient cells

The same process;High successful cultivation rate>90%

a1_icon2.svg
Competent cells

Billion level cells;Highly specific T cells

a1_icon3.svg
Affordable

Feeder cells-free;Non-viral vector at a low cost

a1_icon4.svg
Clinically applicable

Less intensive pretreatment;IL-2 injection-free

Technological platforms

  • DeepTIL®cell expansion platform
    • Highly efficient TIL enrichment for all tumor types

      Clinical-grade TILs can be obtained with a high successful rate >90%

    • Simplified process without feeder cells

      The expansion of TILs becomes easier and cheaper with no healthy human PBMCs.

    • No lymphodepletion pre-treatment or IL-2 injections

      Patients can receive treatment just in general wards.

    22.jpg
  • NovaGMP® gene modification platform
    • Safer

      No risk of wild-type virus mutaions.

    • Cheaper

      The non-viral vector-based gene modification costs less than 1/10 of the viral vectors system.

    • More efficient

      TILs have stronger anti-tumor activity and in vivo adaptation capability with transfection efficiency >45%.

    weibiaoti-1.jpg